1.7 semaglutide to tirzepatide and key differences, weight loss results (2026) Switching from semaglutide to tirzepatide

Excessive intracellular copper levels induce cell death mechanisms such as autophagy and ferroptosis

Finally, owing to inherent limitations of the database, specific causes of mortality were unavailable, which may have led to misclassification of clinical endpoints

Jump to: Headline numbers | How retatrutide and Wegovy work | Why retatrutide produces more weight loss | Side effects compared | Cardiovascular and long-term safety | Muscle and lean mass | Drug interactions and contraception | Mental health | UK access today vs the realistic timeline | Switching considerations | Who should consider which | FAQs | Take home message | Second Natures Mounjaro programme | References In Phase 3 human trials, retatrutide leads to more average weight loss than Wegovy

Always consult healthcare providers for personalized risk assessment and treatment options, and report adverse events to FDA MedWatch